Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EP Study Clear all
Active, not recruiting Phase 1Phase 2 Interventional Results available

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

NCT04251117
View directory record Official record
Conditions
HCC
Interventions
GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
Biological · Drug · Device
Lead sponsor
Geneos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 2:55 PM EDT
Completed No phase listed Observational

Surface ECG Signal Recording for the Implantable Subcutaneous String Defibrillator (ISSD) Detection Algorithm Performance Assessment

NCT03408951
View directory record Official record
Conditions
Tachyarrhythmia, Arrhythmias, Cardiac
Interventions
Recording
Other
Lead sponsor
NewPace Ltd
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

NCT03535194
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab, Placebo, Secukinumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

NCT02464670
View directory record Official record
Conditions
Ebola Vaccine
Interventions
INO-4201, INO-4202, INO-4212, INO-4212 + INO-9012, INO-4201 + INO-9012
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 22, 2026, 2:55 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT04015700
View directory record Official record
Conditions
Glioblastoma
Interventions
Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, Plasmid encoded IL-12
Biological · Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 22, 2026, 2:55 PM EDT
Completed No phase listed Observational

Surface Electrocardiogram (ECG) Signal Recording for Implantable Subcutaneous String Defibrillator (ISSD) Development

NCT02991716
View directory record Official record
Conditions
Arrhythmia, Cardiac
Interventions
recorded patients
Other
Lead sponsor
NewPace Ltd
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlantis, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 22, 2026, 2:55 PM EDT
Terminated No phase listed Observational

Activation Timing and Atrial Fibrillation

NCT02063191
View directory record Official record
Conditions
Arrhythmias, Cardiac, Atrial Fibrillation, Bundle Branch Block
Interventions
Not listed
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 22, 2026, 2:55 PM EDT
Terminated Not applicable Interventional Results available

A Study of Non-invasive Measurement of Blood Glucose and Blood Pressure

NCT05904769
View directory record Official record
Conditions
Diabetes
Interventions
LIFELEAF Smartwatch
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 22, 2026, 2:55 PM EDT
Not listed Phase 1 Interventional

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)

NCT00532974
View directory record Official record
Conditions
HIV Infections
Interventions
EP1090
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
West Hollywood, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Trial of pIL-12 Electroporation Malignant Melanoma

NCT01502293
View directory record Official record
Conditions
Melanoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

NCT00685412
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
VGX-3100
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 22, 2026, 2:55 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy of the EarPopper Device in Children With Recurrent Otitis Media

NCT03534219
View directory record Official record
Conditions
Recurrent Acute Otitis Media, Acute Otitis Media
Interventions
EarPopper
Device
Lead sponsor
Northwell Health
Other
Eligibility
4 Years to 11 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 22, 2026, 2:55 PM EDT
Not listed Phase 2 Interventional

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

NCT03567720
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
tavokinogene telseplasmid, Pembrolizumab, Immunopulse, nab paclitaxel, gemcitabine plus carboplatin
Biological · Device · Drug
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 22, 2026, 2:55 PM EDT
Completed No phase listed Observational

Redo AF Sub Study (of the Pure EP 2.0 Main Study)

NCT04964440
View directory record Official record
Conditions
Atrial Fibrillation Recurrent
Interventions
Pure-EP
Device
Lead sponsor
BioSig Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

NCT04336410
View directory record Official record
Conditions
Coronavirus Infection
Interventions
INO-4800, CELLECTRA® 2000
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

NCT01188850
View directory record Official record
Conditions
Human Papillomavirus (HPV)
Interventions
VGX-3100
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 46 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Hopwood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

NCT00052182
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 23, 2007 · Synced Oct 22, 2026, 2:55 PM EDT
Not listed No phase listed Observational

South Asian Arrhythmogenic Cardiomyopathy Registry

NCT04895540
View directory record Official record
Conditions
Arrhythmogenic Right Ventricular Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Ventricular Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Tachycardia, Sudden Cardiac Death
Interventions
ECG, Echocardiography, Cardiac MRI, Ambulatory ECG recording, Cardiac EP study, All study subjects will undergo sample collection for genetic testing.
Diagnostic Test · Genetic
Lead sponsor
Sheri Kashmir Institute of Medical Sciences
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

NCT00926640
View directory record Official record
Conditions
Carcinoma Neuroendocrine, Small Cell Lung Carcinoma, Malignant Epithelial Neoplasms
Interventions
Belinostat, Cisplatin, Etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

NCT01260727
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 2:55 PM EDT
Not listed No phase listed Observational

Assessing the Predictive Value of High Frequency Algorithm of PURE EP for Low Amplitude Signal Detection

NCT05450302
View directory record Official record
Conditions
Cardiac Arrhythmias
Interventions
PURE EP (Observational Study)
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 22, 2026, 2:55 PM EDT
Terminated Not applicable Interventional Results available

My Dose Coach Mobile App to Support Insulin Titration and Maintenance

NCT04678661
View directory record Official record
Conditions
Diabetes Mellitus Type 2 - Insulin-Treated
Interventions
Smartphone application and web portal, Standard Insulin Therapy Education
Device · Behavioral
Lead sponsor
Linda Siminerio
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 22, 2026, 2:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872
View directory record Official record
Conditions
Small Cell Lung Carcinoma Extensive Disease
Interventions
Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View directory record Official record
Conditions
HIV-1-infection
Interventions
PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
Biological · Device
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 22, 2026, 2:55 PM EDT